Ocugen Stock Price

-0.6132 (-5.62%)
Upgrade to Real-Time
Regular Market


52 Week Range


Best deals to access real time data!
CHART Trader
Monthly Subscription
for only
Canadian Level 1 + USA
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Ocugen Inc OCGN NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-0.6132 -5.62% 10.2968 09:39:28
Open Price Low Price High Price Close Price Prev Close
9.61 9.50 10.45 10.91
Bid Price Ask Price Spread News
10.28 10.30 0.02 - 1
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
59,635 14,481,951 $ 10.08 $ 145,935,663 83,267,004 0.17 - 18.77
Last Trade Time Type Quantity Stock Price Currency
09:39:28 28 $ 10.2878 USD

Ocugen Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
$ 1.83B 188.17M 182.91M $ 42.62k $ - -0.31 -40.90
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - 1.50%

more financials information »

Ocugen News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical OCGN Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week11.0016.209.5013.40153,506,904-0.7032-6.39%
1 Month7.0716.205.237510.88111,830,0523.2345.64%
3 Months9.6016.205.237510.3060,251,2500.69687.26%
6 Months0.291118.770.27277.1068,577,68510.013,437.2%
1 Year0.3418.770.175.5343,658,7009.962,928.47%
3 Years3.2418.770.175.2129,079,1627.06217.8%
5 Years3.2418.770.175.2129,079,1627.06217.8%

Ocugen Description

Ocugen Inc is a clinical-stage biopharmaceutical company. It is focused on discovering, developing and commercializing a pipeline of innovative therapies that address rare and underserved eye diseases. Ocugen offers a diversified ophthalmology portfolio that includes novel gene therapies, biologics, and small molecules and targets a broad range of high-need retinal and ocular surface diseases. Its product candidate includes OCU200 and OCU300 to treat diabetic macular edema (DME), diabetic retinopathy (DR) and wet age-related macular degeneration (AMD).

Your Recent History
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.